Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Wisee who wrote (460)	4/24/1998 7:01:00 PM
From: Saracen	Read Replies (2) \| Respond to of 1185

It is true - I am new to SI. I just signed on yesterday, but I have been following the different threads for over a year. I have been an active investor in V.S.E. stocks now for over 12 years. I have a close friend who was one of the original financiers behind Nortran. I am down now to only 10,000 shares, but up until last year's run in the stock price, I owned over 400,000 shares. I am confident that a major deal will be done, sooner rather than later, with a major drug company (Hoffman LaRoche or whomever!). I am also confident that we will see news shortly regarding a T.S.E. listing for Nortran (need to get off the god-forsaken V.S.E.). As to today's news, I am a little disappointed, for two reasons: the excessive discount of the financing to the current market price, and the choice of Canaccord as a co-lead on the financing. Both Gordon Capital and Goepel are perfectly acceptable and reputable firms, but Canaccord and its chief, Peter Brown (a.k.a. "The Rabbit"), have horrible reputations, having been involved in numerous V.S.E. scams. We will see how the market reacts on Monday. I remain very positive about Nortran's potential, and so I believe that the stock will do very well in the long run.